69 POSTER Evaluating the duel kinase inhibitor lapatinib: Bioanalytical method development and pharmacokinetic analysis in mouse, rat, and human and determination of in vivo effica... by Cooper, J, Nieves, F.E, Kuhn, J, Takimoto, C.H, Tolcher, A.W, Wick, M.J

Get full text

72 POSTER Preclinical evaluation of the tyrosine kinase inhibitor erlotinib: Bioanalytical method development and pharmacokinetic analysis and in vivo evaluation and comparison in... by Nieves, F.E, Cooper, J, Mangold, G.L, Kuhn, J, Takimoto, C.H, Tolcher, A.W, Wick, M.J

Get full text

75 POSTER Establishment, validation, and in vivo evaluation of tumor explant models of adenoid cystic carcinoma: effects of FDA-approved and candidate therapies in human ACC xenogr... by Nieves, F.E, Moskaluk, C.A, Sidransky, D, Takimoto, C.H, Tolcher, A.W, Kaufman, J, Wick, M.J

Get full text

THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS by Advani, R., Bartlett, N.L., Smith, S.M., Roschewski, M., Popplewell, L., Flinn, I., Collins, G., Ghosh, N., LaCasce, A., Asch, A., Kline, J., Kesevan, M., Tran, T., Lynn, J., Huang, J., Agoram, B., Volkmer, J., Takimoto, C.H., Chao, M.P., Mehta, A.

Get full text

13 INVITED Phase zero clinical-trials in oncology: a new paradigm for early drug development? by Takimoto, C.H.

Get full text

708 POSTER AMG 386, a first-in-class, selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors by Mita, A, Wang, D, Takimoto, C.H, Martin, D, Nguyen, L, Rasmussen, E, Storgard, C, LoRusso, P

Get full text

514 Pharmacokinetic study of the distribution, metabolism and excretion of non-radiolabeled DX 8951f following repeated intravenous administration to patients with solid tumors by Beeram, M., Rowinsky, E.K., Patnaik, A., Mita, A., Forero, L., Wood, L., Tolcher, A.W., Kamida, M., De Jager, R.L., Takimoto, C.H.

Get full text

387 A phase I study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases by Dumez, H., Clement, P., Takimoto, C.H., van Oosterom, A.T., Mita, A., Parker, K., Rowinsky, E.K., Salazar, R., Martinelli, E., Baselga, J.

Get full text

412 A phase I and pharmacokinetic study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases by Mita, A., Takimoto, C.H., Martinelli, E., Dumez, H., DiLea, C., Mietlowski, W., Tabernero, J., Dugan, M., Isambert, N., van Oosterom, A.T.

Get full text

Effects of 5-fluorouracil substitution on the RNA conformation and in vitro translation of thymidylate synthase messenger RNA by TAKIMOTO, C. H, VOELLER, D. B, STRONG, J. M, ANDERSON, L, CHU, E, ALLEGRA, C. J

Get full text